Having recognized this trend, the National Cancer Institute's AIDS Malignancy Consortium requires baseline anal Pap screening and anoscopy as part of all its trial protocols, said Dr.
What does AMC stand for?
AMC stands for AIDS Malignancy Consortium (National Cancer Institute-supported clinical trials group)
This definition appears frequently and is found in the following Acronym Finder categories:
- Military and Government
- Science, medicine, engineering, etc.
- Organizations, NGOs, schools, universities, etc.
See other definitions of AMC
We have 864 other meanings of AMC in our Acronym Attic
- Advances in Mathematics of Communications
- Aegis Mortgage Corporation (various locations)
- Aerospace Medical Council
- Aerospace Museum of California (McClellan, CA)
- African Metals Corporation
- After Market Close
- Agape Mission Church
- Agricultural and Mechanical College of Texas
- Aid Management and Coordination (UN)
- Aides Médicales et Charité (French: Medical Aid and Charity; Togo)
Samples in periodicals archive:
The trial was conducted by the AIDS Malignancy Consortium at the University of California in San Francisco and was sponsored by the U.
The AIDS Malignancy Consortium (AMC) was developed in 1995 to expedite the rapid evaluation of hypothesis-driven Phase I, II, and III multicenter clinical trials that utilize the expertise of both NCI--and NIAID-sponsored scientists.
First NCI-Sponsored Trial Tests Stressgen's Proprietary Fusion Technology in HIV-Positive High-Risk Dysplasia Patients Stressgen Biotechnologies Corporation (TSX:SSB) today announced that the AIDS Malignancy Consortium sponsored by the U.
NASDAQ:CGPI) today announced that the AIDS Malignancy Consortium (AMC) has completed enrollment in and closed to accrual a Phase II study evaluating the efficacy of Metastat(R), an orally-active angiogenesis inhibitor developed by CollaGenex Pharmaceuticals, in treating HIV-related Kaposi's sarcoma (KS).
StressGen intends to support a Phase II trial, funded by the National Cancer Institute (NCI) through the AIDS Malignancy Consortium, in AIN patients with HIV during the first quarter of 2000.
The study was carried out by the AIDS Malignancy Consortium and was sponsored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement between the NCI and CollaGenex.
The two Phase II studies were similar in design, with one conducted by the AIDS Malignancy Consortium (AMC) sponsored by NCI and the other sponsored directly by Ligand.